Figure 1
From: Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis
Sevoflurane attenuates development of clinical scores in experimental autoimmune encephalomyelitis (EAE). Female C57Bl/6 mice were immunized with myelin oligodendrocyte glycoprotein (MOG)35–55 peptide to develop EAE as described in the Methods section. At 10 days after the MOG booster, the mice were subjected to 2 h of 2.5% sevoflurane in 100% oxygen (open circles), or 100% oxygen alone (filled circles). Clinical scores were monitored for the next 4 weeks. (A) Daily incidence of disease over the course of the study for both groups. (B) Mean ± SEM of average clinical scores of one experiment performed with n = 7 mice per group; similar results were obtained in a second independent study. F[9,1] = 1.98, P = 0.049, two-way repeated measures analysis of variance (ANOVA).